Zobrazeno 1 - 10
of 51
pro vyhledávání: '"Rumana Rafiq"'
Autor:
Stephen J. Pettitt, Dragomir B. Krastev, Inger Brandsma, Amy Dréan, Feifei Song, Radoslav Aleksandrov, Maria I. Harrell, Malini Menon, Rachel Brough, James Campbell, Jessica Frankum, Michael Ranes, Helen N. Pemberton, Rumana Rafiq, Kerry Fenwick, Amanda Swain, Sebastian Guettler, Jung-Min Lee, Elizabeth M. Swisher, Stoyno Stoynov, Kosuke Yusa, Alan Ashworth, Christopher J. Lord
Publikováno v:
Nature Communications, Vol 9, Iss 1, Pp 1-14 (2018)
The mechanisms of PARP inhibitor (PARPi) resistance are poorly understood. Here the authors employ a CRISPR mutagenesis approach to identify PARP1 mutants causing PARPi resistance and find that PARP1 mutations are tolerated in BRCA1 mutated cells, su
Externí odkaz:
https://doaj.org/article/1eb977c74fb546b0a7321e49be5d0643
Autor:
Chris T. Williamson, Rowan Miller, Helen N. Pemberton, Samuel E. Jones, James Campbell, Asha Konde, Nicholas Badham, Rumana Rafiq, Rachel Brough, Aditi Gulati, Colm J. Ryan, Jeff Francis, Peter B. Vermulen, Andrew R. Reynolds, Philip M. Reaper, John R. Pollard, Alan Ashworth, Christopher J. Lord
Publikováno v:
Nature Communications, Vol 7, Iss 1, Pp 1-13 (2016)
Mutations in the BAF SWI/SNF complex subunits are frequent in cancers but selective therapeutic approaches are not available yet. Here, the authors demonstrate that defects ofARID1Aand other subunits sensitizes cancer cells to the DNA checkpoint kina
Externí odkaz:
https://doaj.org/article/e641244f3cf24d9e87d1e6540b5b48bf
Autor:
James Campbell, Colm J. Ryan, Rachel Brough, Ilirjana Bajrami, Helen N. Pemberton, Irene Y. Chong, Sara Costa-Cabral, Jessica Frankum, Aditi Gulati, Harriet Holme, Rowan Miller, Sophie Postel-Vinay, Rumana Rafiq, Wenbin Wei, Chris T. Williamson, David A. Quigley, Joe Tym, Bissan Al-Lazikani, Timothy Fenton, Rachael Natrajan, Sandra J. Strauss, Alan Ashworth, Christopher J. Lord
Publikováno v:
Cell Reports, Vol 14, Iss 10, Pp 2490-2501 (2016)
One approach to identifying cancer-specific vulnerabilities and therapeutic targets is to profile genetic dependencies in cancer cell lines. Here, we describe data from a series of siRNA screens that identify the kinase genetic dependencies in 117 ca
Externí odkaz:
https://doaj.org/article/381f961b73404d2fa41627417ce941fc
Autor:
Christopher J. Lord, Alan Ashworth, Stephen J. Pettitt, Nicholas C. Turner, Aditi Gulati, James Campbell, Nicholas Badham, Rumana Rafiq, Jessica Frankum, Helen N. Pemberton, Isaac Garcia-Murillas, Asha Konde, Malini Menon, Inger Brandsma, Rachel Brough, Chris T. Williamson, Amy Dréan
Figure S1: Characterisation of CAPAN1-B2S* Figure S2: Characterisation of SUM149-B1S* Figure S3: Sensitivity of ddPCR assay. Figure S4: Olaparib and talazoparib select for secondary mutant tumour cells. Figure S5: DLD1 tumour cells have a fitness adv
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5c87fbc8e38f13dde6b24d9910847b29
https://doi.org/10.1158/1535-7163.22508823.v1
https://doi.org/10.1158/1535-7163.22508823.v1
Autor:
Alan Ashworth, Christopher J. Lord, Sourav Bandyopadhyay, Kevan M. Shokat, Rebecca S. Levin, James T. Webber, John D. Gordan, Chris Torrance, Jonathan D. Moore, Claire Mahoney, Holly Astley, Josephine Joel, Rachel Natrajan, Helen Pemberton, Rumana Rafiq, Asha Kigozi, James Campbell, Simon McDade, Chris T. Williamson, Ilirjana Bajrami, Rachel Brough, Rowan E. Miller
Supplier and catalogue number of compounds included in high-throughput drug screen
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::373d13022c92315ae677f6d84de762c1
https://doi.org/10.1158/1535-7163.22507552.v1
https://doi.org/10.1158/1535-7163.22507552.v1
Autor:
Christopher J. Lord, Alan Ashworth, Andrew N.J. Tutt, Jos Jonkers, Patrick W.B. Derksen, Colm J. Ryan, Rachael Natrajan, Spiros Linardopoulos, Mitch Dowsett, Lesley-Ann Martin, Elinor J. Sawyer, Fredrik Wallberg, Patrycja Gazinska, Irene Chong, Marta Llorca Cardenosa, Mark D. Gurden, Stephen J. Pettitt, Rahul Kumar, Aditi Gulati, James Campbell, Malini Menon, Dragomir B. Krastev, Asha Konde, Rumana Rafiq, Feifei Song, Jessica Frankum, Helen N. Pemberton, Rachel Brough, Marieke van de Ven, Rebecca Marlow, Ilirjana Bajrami
Lagging chromosomes in E-cadherin defective cell exposed to foretinib leading to failed cytokinesis
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a46a503990fcd013cf24e9120ca5907e
https://doi.org/10.1158/2159-8290.22532777.v1
https://doi.org/10.1158/2159-8290.22532777.v1
Autor:
Alan Ashworth, Christopher J. Lord, Sourav Bandyopadhyay, Kevan M. Shokat, Rebecca S. Levin, James T. Webber, John D. Gordan, Chris Torrance, Jonathan D. Moore, Claire Mahoney, Holly Astley, Josephine Joel, Rachel Natrajan, Helen Pemberton, Rumana Rafiq, Asha Kigozi, James Campbell, Simon McDade, Chris T. Williamson, Ilirjana Bajrami, Rachel Brough, Rowan E. Miller
Additional compounds included in the isogenic high-throughput drug screen
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5821d655b15b0e0045324aa26cbbbacc
https://doi.org/10.1158/1535-7163.22507534.v1
https://doi.org/10.1158/1535-7163.22507534.v1
Autor:
Alan Ashworth, Christopher J. Lord, Sourav Bandyopadhyay, Kevan M. Shokat, Rebecca S. Levin, James T. Webber, John D. Gordan, Chris Torrance, Jonathan D. Moore, Claire Mahoney, Holly Astley, Josephine Joel, Rachel Natrajan, Helen Pemberton, Rumana Rafiq, Asha Kigozi, James Campbell, Simon McDade, Chris T. Williamson, Ilirjana Bajrami, Rachel Brough, Rowan E. Miller
Supplementary Figure 1 ARID1A mutations in the panel of OCCC tumour cell line models with corresponding protein expression. Supplementary Figure 2 Un-cropped western blots from main and supplementary figures. Supplementary Figure 3 ARID1A selective e
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0c4d5e637be03d18a6d8e584452ea31a
https://doi.org/10.1158/1535-7163.22507555.v1
https://doi.org/10.1158/1535-7163.22507555.v1
Autor:
Christopher J. Lord, Alan Ashworth, Andrew N.J. Tutt, Jos Jonkers, Patrick W.B. Derksen, Colm J. Ryan, Rachael Natrajan, Spiros Linardopoulos, Mitch Dowsett, Lesley-Ann Martin, Elinor J. Sawyer, Fredrik Wallberg, Patrycja Gazinska, Irene Chong, Marta Llorca Cardenosa, Mark D. Gurden, Stephen J. Pettitt, Rahul Kumar, Aditi Gulati, James Campbell, Malini Menon, Dragomir B. Krastev, Asha Konde, Rumana Rafiq, Feifei Song, Jessica Frankum, Helen N. Pemberton, Rachel Brough, Marieke van de Ven, Rebecca Marlow, Ilirjana Bajrami
The cell adhesion glycoprotein E-cadherin (CDH1) is commonly inactivated in breast tumors. Precision medicine approaches that exploit this characteristic are not available. Using perturbation screens in breast tumor cells with CRISPR/Cas9-engineered
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::06a759d0659ac60046b51092f46f3457
https://doi.org/10.1158/2159-8290.c.6546827
https://doi.org/10.1158/2159-8290.c.6546827
Autor:
Alan Ashworth, Christopher J. Lord, Sourav Bandyopadhyay, Kevan M. Shokat, Rebecca S. Levin, James T. Webber, John D. Gordan, Chris Torrance, Jonathan D. Moore, Claire Mahoney, Holly Astley, Josephine Joel, Rachel Natrajan, Helen Pemberton, Rumana Rafiq, Asha Kigozi, James Campbell, Simon McDade, Chris T. Williamson, Ilirjana Bajrami, Rachel Brough, Rowan E. Miller
siRNA library gene list for dasatinib resistance screen, see also figure 5
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::965c604b86d9c18e6e6f0ff928f453bd
https://doi.org/10.1158/1535-7163.22507531
https://doi.org/10.1158/1535-7163.22507531